In short
Clinical trials are investigating HUMAN IGG1 BISPECIFIC MONOCLONAL ANTIBODY AGAINST KALLIKREIN-5 AND KALLIKREIN-7 in adults with moderate to severe atopic dermatitis. The studies aim to evaluate efficacy and safety, with outcomes measured after treatment. This article summarizes the trial purpose, phase, target population, and main endpoint.
Key points
- Clinical trials are investigating HUMAN IGG1 BISPECIFIC MONOCLONAL ANTIBODY AGAINST KALLIKREIN-5 AND KALLIKREIN-7 in adults with moderate to severe atopic dermatitis. The study is an interventional Phase 2 trial and is authorised. It compares the study treatment with placebo. The planned enrollment is 90 participants. The main endpoint is the percentage of participants with improvement of atopic dermatitis at Week 16. The trial is designed to look at both efficacy and safety.
Trial overview
The available trial is a study to investigate the efficacy and safety of HUMAN IGG1 BISPECIFIC MONOCLONAL ANTIBODY AGAINST KALLIKREIN-5 AND KALLIKREIN-7 compared with placebo in adults with moderate to severe atopic dermatitis.
The study is described as an interventional trial, which means researchers assign a study treatment and then measure the results.
Study design and treatment comparison
This trial compares TRIV-509 with a placebo, which is a look-alike treatment used for comparison.
The brief summary says the study is assessing TRIV-509 given by subcutaneous injection for 12 weeks in adults with moderate to severe atopic dermatitis.
The source also lists TRIV-509 placebo as the comparison treatment in the study.
Who can participate
The trial is focused on adults with moderate to severe atopic dermatitis.
No other participant rules are provided in the source data, so the available information only confirms the age group and the condition being studied.
What the trial measures
The primary outcome is the percentage of participants with improvement of atopic dermatitis at Week 16.
This means the study will measure how many people improved after treatment, using a specific time point in the study schedule.
The trial summary also shows that the study aims to assess efficacy and safety, so both benefit and tolerability are part of the research goal.
Trial status and size
The trial status is Authorised.
It is a Phase 2 study with planned enrollment of 90 participants.
Phase 2 trials usually help researchers learn more about whether a treatment may work while continuing to monitor safety, and this study fits that research stage.